Moderna Covid-19 vaccine gets Phase 2 study green light

Moderna Covid-19 vaccine gets Phase 2 study green light

PanARMENIAN.Net - The promising coronavirus vaccine developed by Cambridge-based company Moderna was cleared by the FDA for a phase 2 study, a step that will push the much needed vaccine forward, Boston Herald reports.

Moderna Therapeutics, a Cambridge, Mass.-based biotech company co-founded by Armenian entrepreneur Noubar Afeyan, shipped the first batches of its Covid-19 vaccine in February.

“The imminent Phase 2 study start is a crucial step forward as we continue to advance the clinical development of mRNA-1273, our vaccine candidate against SARS-CoV-2,” said Stephane Bancel, Moderna’s chief executive officer in a press release issued by the company on Thursday.

Moderna has a goal of starting a pivotal phase 3 study in the summer and could have its first biologics license application approved as soon as next year, Bancel’s statement said.

“We are accelerating manufacturing scale-up and our partnership with Lonza puts us in a position to make and distribute as many vaccine doses of mRNA-1273 as possible, should it prove to be safe and effective,” said Bancel.

 Top stories
For countries not on the exemption list, the advice to avoid non-necessary travel still applies until at least September 1st, 2021.
Ani Samsonyan said all the trials against the Armenian PoWs are fake, aiming to "throw dust in your eyes."
Armenia is included in the orange zone, which means vaccinated travelers are welcome to visit France.
The Armenian Foreign Ministry said it is constantly in touch with the Jerusalem Patriarchate.
Partner news